Gout: Joints and beyond, epidemiology, clinical features, treatment and co-morbidities

Robinson, Philip C. and Horsburgh, Simon (2014) Gout: Joints and beyond, epidemiology, clinical features, treatment and co-morbidities. Maturitas, 78 4: 245-251. doi:10.1016/j.maturitas.2014.05.001


Author Robinson, Philip C.
Horsburgh, Simon
Title Gout: Joints and beyond, epidemiology, clinical features, treatment and co-morbidities
Journal name Maturitas   Check publisher's open access policy
ISSN 0378-5122
1873-4111
Publication date 2014-01-01
Year available 2014
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1016/j.maturitas.2014.05.001
Volume 78
Issue 4
Start page 245
End page 251
Total pages 7
Place of publication Shannon, County Clare Ireland
Publisher Elsevier Ireland
Collection year 2015
Language eng
Abstract Gout is a common inflammatory arthritis precipitated by an inflammatory reaction to urate crystals in the joint. Gout is increasingly being recognised as a disease primarily of urate overload with arthritis being a consequence of this pathological accumulation. It is associated with a number of important co-morbidities including chronic kidney disease, obesity, diabetes and cardiovascular disease. The prevalence of gout is increasing around the world. Significant progress has been made in determining the genetic basis for both gout and hyperuricaemia. Environmental risk factors for gout have been identified as certain foods, alcohol and several medications. There is, however, little evidence that changing these environmental risks improves gout on an individual level. Treatment of gout encompasses two strategies: firstly treatment of inflammatory arthritis with non-steroidal anti-inflammatories, corticosteroids, colchicine or interleukin-1 inhibitors. The second and most important strategy is urate lowering, to a target of 0.36 mmol/L (6 mg/dL) or potentially lower in those with tophi (collections of crystalline urate subcutaneously). Along with urate lowering, adequate and prolonged gout flare prophylaxis is required to prevent the precipitation of acute attacks. Newer urate lowering agents are in development and have the potential to significantly expand the potential treatment options. Education of patients regarding the importance of life long urate lowering therapy and prophylaxis of acute attacks is critical to treatment success as adherence with medication is low in chronic diseases in general but especially in gout.
Keyword Chronic kidney disease
Diabetes mellitus
Diet
Gout
Hypertension
Urate
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Official 2015 Collection
UQ Diamantina Institute Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 24 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 25 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 12 Aug 2014, 13:43:15 EST by System User on behalf of UQ Diamantina Institute